Product Images Gabapentin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 10 images provide visual information about the product associated with Gabapentin NDC 71093-111 by Aci Healthcare Usa, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

600mg100count vivimed

600mg100count vivimed

This is a description for the usage and storage of Gabapentin tablets. The dosage information is available in the package insert, and the tablets should be stored at controlled room temperature between 20°C to 25°C (68° to 77°F). The tablets can be temporarily stored between 15°C to 30°C (59°F to 86°F). The tablets should be dispensed in a light, airtight container with a child-resistant closure. The manufacturer is Vivined it Sciences Privte Linited, and the distributor is ACI Healthcare USA, Inc. The medication guide should be provided separately to each patient. The tablets contain 600mg of Gabapentin USP.*

800mg500count vivimed

800mg500count vivimed

This is medication information for Gabapentin tablets, USP with the dosage information mentioned in the package insert. The medication should be stored at a temperature between 20°C to 25°C. It's essential to dispense the medication in a container defined by the USP, with child-resistant closure. The package also advises keeping all medications out of the reach of children. The package contains 500 film-coated tablets of Gabapentin, USP with each tablet containing 800mg of gabapentin. It also has a medication guide, which the pharmacist should provide separately to each patient. The rest of the text contains manufacturing and distribution information.*

Figure 1 - ab1e0185 b802 4cf2 a5d4 b71f27f1dcb0 00

Figure 1 - ab1e0185 b802 4cf2 a5d4 b71f27f1dcb0 00

This is a formula to calculate creatinine clearance (CLCr) in patients based on their age, weight, and serum creatinine level. The formula differs for female patients, where the result is multiplied by 0.85.*

containerlabel 600mg strides

containerlabel 600mg strides

NDC 71093-111-04 is a medication called "Roonly" with a typical dosage that can be found in the package insert. It should be stored between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C, in a tight, light-resistant container as defined in USP, with a child-resistant closure. The manufacturer is Sides Pharma Science Limited, and each in-coated bucket contains 600mg Gabapentin, USP.*

containerlabel 800mg strides

containerlabel 800mg strides

NDC 71083-112:05 R only Gabapentin Tablets, USP is a medicine that comes in a container of 500 film-coated tablets each containing 800mg of Gabapentin USP. The usual dosage is mentioned on the package insert provided for full prescribing information. It should be stored at temperatures between 20°C - 25°C (68°F - 77°F) and away from children. Manufactured by Strides Pharma Science Limited in India and distributed by ACI Healthcare USA, Inc. in Coral Springs, Florida. Dispense only in a tight, light-resistant container as defined by USP, with a child-resistant closure.*

Chem Structure - d45f499b 8612 479e 8dd2 4fe28b1f5f9c 01

Chem Structure - d45f499b 8612 479e 8dd2 4fe28b1f5f9c 01

figure01 - d45f499b 8612 479e 8dd2 4fe28b1f5f9c 02

figure01 - d45f499b 8612 479e 8dd2 4fe28b1f5f9c 02

figure02 - d45f499b 8612 479e 8dd2 4fe28b1f5f9c 03

figure02 - d45f499b 8612 479e 8dd2 4fe28b1f5f9c 03

This appears to be a portion of a chart or graph from a medical study evaluating the effectiveness of different doses of Gabapentin for pain relief over a 4-week period. The doses tested were 1800mg/day and 2400mg/day, compared to a placebo treatment. The chart tracks the mean pain score over the 7-day evaluation period.*

figure03 - d45f499b 8612 479e 8dd2 4fe28b1f5f9c 04

figure03 - d45f499b 8612 479e 8dd2 4fe28b1f5f9c 04

The text provides statistical data on the proportion of responders i.e patients with more than a 50% reduction in pain score, at the endpoint of controlled PHN (Postherpetic Neuralgia) studies. Study 1 and Study 2 are compared in terms of the proportion of responders they produce for treatments, GBP3600 and GBP2400. The results show that Study 2 produced higher proportion of responders (34%) in comparison to study 1 (32%). However, there is no information available regarding the context of the study and more details regarding the treatments, Study 1, and Study 2.*

figure4 - d45f499b 8612 479e 8dd2 4fe28b1f5f9c 05

figure4 - d45f499b 8612 479e 8dd2 4fe28b1f5f9c 05

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.